Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026)
Neurogene (NGNE) posted Depreciation & Amortization (CF) of $800000.0 for Q1 2026, up 9.14% on a QoQ basis from $733000.0 in Q4 2025, and up 6.81% year-over-year from $749000.0 in Q1 2025.
Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Neurogene's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.81% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (changed 0.19% YoY) and the FY2025 annual result came in at $3.0 million, down 6.25% from the prior year.
- Depreciation & Amortization (CF) was $800000.0 for Q1 2026 at Neurogene, up from $733000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.0 million in Q4 2022 and bottomed at $323000.0 in Q3 2022.
- A 5-year average of $798352.9 and a median of $800000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 414.62% — and 2023, when it slumped 55.16%.
- Neurogene's Depreciation & Amortization (CF) stood at $2.0 million in 2022, then slumped by 55.16% to $900000.0 in 2023, then retreated by 12.22% to $790000.0 in 2024, then declined by 7.22% to $733000.0 in 2025, then climbed by 9.14% to $800000.0 in 2026.
- Business Quant data shows NGNE's Depreciation & Amortization (CF) at $800000.0 in Q1 2026, $733000.0 in Q4 2025, and $800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |